MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans short-read sequencing, long-read nanopore sequencing, generative lab intelligence (GLI), and spatial omics technologies. MGI stated that this step positions it as the only manufacturer offering these core life science tools under one provider.

STOmics, established in April 2024, contributes its proprietary Stereo-seq spatial multi-omics technology. Key features include a large field of view, nano-scale resolution, unbiased whole-transcriptome capture, and integrated multi-omics solutions. The technology has been widely applied in developmental biology, organ atlas mapping, neuroscience, and digital pathology, and has contributed to more than 60 publications in journals such as Cell, Science, Nature, and Cell Research.

STOmics’ solutions are compatible with MGI’s patented DNBSEQ sequencing platform; Stereo-seq libraries are sequenced on MGI’s G400 and T7 instruments to deliver high-quality data. Following the acquisition, MGI states it can offer more accessible, comprehensive, and efficient spatial-temporal omics workflow solutions to enable deeper, three-dimensional biological insights.

CycloneSEQ, founded in March 2024, has commercialized nanopore sequencing across two platforms: the G100-ER for lower throughput and the G400-ER for higher throughput. The G100-ER has obtained CE marking under the European Union’s In Vitro Diagnostic Regulation (IVDR). MGI’s DNBSEQ technology, described as high-throughput, high-accuracy, and cost-effective, complements CycloneSEQ’s long-read capabilities to provide a combined “long-read + short-read” toolkit.

Both STOmics and CycloneSEQ had previously collaborated closely with MGI, which held exclusive global distribution licenses for their reagents and products. With integration of short-read, long-read, and spatial omics under one provider, and inclusion of generative lab intelligence, the “SEQALL+GLI+Omics” strategy is intended to enhance customer service capabilities, operational efficiency, and long-term partnership value. The announcement notes that the information is for general reference only and does not imply that any product or service will be available in a specific country or region.

Related Links
MGI Tech